Ebola: Tracking the Latest Measures Against a Killer
To read the full Life Sciences report, please click here.
As the Ebola Virus Disease (EVD) crisis unfolds in West Africa at this writing, the number of confirmed or suspected cases, as compiled by the World Health Organization, exceeds 2,000, with deaths now surpassing half that number. This episode is the largest in a series of intermittent outbreaks stretching back nearly four decades to when the causative virus was first isolated in 1976.
At present, there is no effective treatment or vaccine for EVD, although the biomedical and public-health establishment, compelled by the potentially global threat of a disease capable of killing upwards of 90% of those infected, has vigorously pursued countermeasures.
Thomson Reuters Life Sciences resources have tracked the latest efforts at the treatment and prevention of EVD, in a report entitled “Focus on Ebola: New Strategies in Discovery and Design of Therapies Against the Lethal Disease.” After reviewing the natural history of the virus and the mechanism of human infection, the report specifies the most promising agents currently under investigation.
The report includes a listing of anti-EVD compounds and their present status. The table is excerpted below.
The full Life Sciences report can be accessed here.
Drugs and Biologics Under Active Investigation for the Prevention and Treatment of Ebola Virus Disease
|AVI-7537||Sarepta Therapeutics||Antisense oligomer based on the NeuGene(R) technology that targets specific VP24 Ebola virus gene translational start site (EBOV VP24 - specific PMO)||Phase I|
|Ebola SNALP||Tekmira||Combination of small interfering RNAs with 2'-O- methyl versions of guanines and uridines (EK - 1 mod, VP24 - 1160 mod and VP35 - 855 mod) respectively targeting the Zaire Ebola virus L, VP and VP35 genes formulated in stable nucleic acid lipid particles (SNALPs)||Phase I|
|ZMapp||Public Health Agency of Canada/ Mapp Biopharmaceutical/ US Army Med Res Inst Infectious Diseases/ Defyrus||Optimized cocktail combination of three humanized monoclonal antibodies targeting epitopes of Ebola virus (EBOV), comprising the best components of MB - 003 and ZMAb antibodies; produced in Nicotiana plants||Clinical|
|Ad5-optZGP/DEF-201||Defyrus||Combination of DEF-201 with an Ebola vaccine||Preclinical|
|BCX-4430||BioCryst||(2S, 3S, 4R, 5R)-2-(4 -Amino-5H-pyrrolo[3, 2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol||Preclinical|
|BNSP-333-GP||US Department of Health & Human Services||Bivalent vaccine consisting of recombinant rabies BNSP333 virus carrying the Zaire ebola virus (ZEBOV) Mayinga strain glycoprotein (GP)||Preclinical|
|MB-003||US Army Med Res Inst Infectious Diseases/ Mapp Biopharmaceutical/ Kentucky BioProcessing (KBP)||Mixture of deimmunized mouse - human chimeric monoclonal antibodies (h - 13F6, c13C6 and c6D8) targeting non - overlapping glycoprotein (GP) epitopes of Ebola virus (EBOV); produced via Nicotiana benthamiana (deltaXTFT) - based rapid antibody manufacturing platform (RAMP)||Preclinical|
|MVA-BN Filo||Bavarian Nordic||Cancer vaccine consisting of an attenuated version of the Modified Vaccinia Ankara (MVA - BN) virus encoding a filovirus antigen||Preclinical|
|ZMAb||Public Health Agency of Canada||Combination of three neutralizing monoclonal antibodies, 1H3, 2G4 and 4G7, targeting the soluble glycoprotein (sGP) portion (amino acids 1 to 295), the GP2 and epitopes in the C - terminal portion of GP1of the Ebola virus (EBOV) envelope glycoprotein, respectively||Preclinical|
|rVSV-Ebola||Profectus BioSciences||Recombinant vesicular stomatitis virus (rVSV) expressing surface glycoproteins from Ebola virus||Preclinical|
The data and citation records included in this report are from Thomson Reuters Web of ScienceTM. Web of ScienceTM is a registered trademark of Thomson Reuters. All rights reserved.